Biotech has been one of the worst-performing industry groups this cycle. Investors have got used to it as these stocks have been dead money for much of the past decade.
The late-July breadth thrust provides a breadth thrust regime that lasts for a year (or more if we get additional breadth thrusts between now and mid-2023). In such an environment, near-term oversold...
Bryant R. Riley, chairman and CEO of B. Riley Financial Inc $RILY, and director Randall E. Paulson both filed Form 4s reporting purchases for a combined $3.7 million. Both executives have been frequent buyers all year.
